19 days ago
ARGX
AnalystsSamantha SemenkowSamantha Semenkow's Stock Forecasts
AnalystsSamantha Semenkow
Sectors:
Analyst Ranking
Top 19%
#1023 out of 5346 analysts
Average Return
+8.21%
Win Rate
54%44 out of 82
Risk vs Reward
Poor
Good
Samantha Semenkow's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Spyre Therapeutics IncSYRE | +217.33% | $33.06 | $104.91 | 2025-12-17 - 2026-08-07 | Strong Buy |
Roivant Sciences LtdROIV | +193.30% | $12.39 | $36.34 | 2025-09-02 - 2026-08-07 | Strong Buy |
Morphic Holding IncMORF | +109.75% | $27.17 | $56.99 | 2023-12-08 - 2024-08-16 | Strong Buy |
Larimar Therapeutics IncLRMR | +103.34% | $3.29 | $6.69 | 2023-11-17 - 2024-11-15 | Strong Buy |
Allogene Therapeutics IncALLO | +96.33% | $1.09 | $2.14 | 2025-05-15 - 2026-05-14 | Strong Buy |
Samantha Semenkow Analyst Color
Get additional color on Samantha Semenkow's coverage of popular stocks
4 months ago
NKTR
5 months ago
NKTR
5 months ago
BIOA
5 months ago
CPRX
6 months ago
ROIV
2 years ago
CABA
2 years ago
EDIT
2 years ago
LRMR
Samantha Semenkow's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Structure Therapeutics IncGPCR | 3 | Strong Buy | $97.00 | +82.54% | Maintains | 2 days ago |
Rhythm Pharmaceuticals IncRYTM | 4 | Strong Buy | $143.00 | +23.67% | Maintains | 4 days ago |
Wave Life Sciences LtdWVE | 4 | Strong Buy | $19.00 | +211.48% | Maintains | 9 days ago |
Agios Pharmaceuticals IncAGIO | 3 | Strong Buy | $52.00 | +61.14% | Maintains | 9 days ago |
Argenx SeARGX | 9 | Strong Buy | $1,182.00 | +36.64% | Maintains | 19 days ago |
Immunovant IncIMVT | 4 | Strong Buy | $61.00 | +52.69% | Maintains | a month ago |
Faeth Therapeutics IncFTH | 3 | Strong Buy | $55.00 | +125.50% | Initiates Coverage On | 3 months ago |
Sab Biotherapeutics IncSABS | 1 | Strong Buy | $11.00 | +182.05% | Initiates Coverage On | 3 months ago |
Roivant Sciences LtdROIV | 5 | Strong Buy | $42.00 | +15.58% | Maintains | 3 months ago |
Catalyst Pharmaceuticals IncCPRX | 5 | Hold | $31.50 | +0.03% | Downgrades | 3 months ago |
Spyre Therapeutics IncSYRE | 2 | Strong Buy | $97.00 | -7.54% | Maintains | 3 months ago |
Nektar TherapeuticsNKTR | 3 | Strong Buy | $151.00 | +97.44% | Maintains | 4 months ago |
Biohaven LtdBHVN | 3 | Strong Buy | $17.00 | +15.96% | Maintains | 4 months ago |
Beam Therapeutics IncBEAM | 4 | Strong Buy | $68.00 | +147.45% | Maintains | 4 months ago |
Bioage Labs IncBIOA | 6 | Strong Buy | $52.00 | +343.69% | Maintains | 5 months ago |
Larimar Therapeutics IncLRMR | 7 | Strong Buy | $14.00 | +236.54% | Maintains | 5 months ago |
Cullinan Therapeutics IncCGEM | 1 | Strong Buy | $33.00 | +86.13% | Initiates Coverage On | 6 months ago |
Amicus Therapeutics IncFOLD | 2 | Hold | $14.50 | +0.07% | Downgrades | 8 months ago |
Prime Medicine IncPRME | 5 | Hold | $4.25 | +37.99% | Maintains | 9 months ago |
Moonlake ImmunotherapeuticsMLTX | 3 | Strong Sell | $5.00 | -72.62% | Downgrades | 9 months ago |
Cabaletta Bio IncCABA | 4 | Strong Buy | $10.00 | +258.42% | Maintains | a year ago |
Allogene Therapeutics IncALLO | 3 | Strong Buy | $4.00 | N/A | Maintains | a year ago |
Acelyrin IncSLRN | 2 | Hold | $3.00 | N/A | Maintains | 2 years ago |
Voyager Therapeutics IncVYGR | 1 | Strong Buy | $12.00 | N/A | Initiates Coverage On | 2 years ago |
Sana Biotechnology IncSANA | 2 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
Editas Medicine IncEDIT | 4 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
2seventy Bio IncTSVT | 2 | Strong Buy | $12.00 | N/A | Maintains | 2 years ago |
Morphic Holding IncMORF | 1 | Strong Buy | $46.00 | N/A | Initiates Coverage On | 3 years ago |
9 Meters Biopharma IncNMTRQ | 3 | Hold | $0.75 | N/A | Maintains | 3 years ago |
Ngm Biopharmaceuticals IncNGM | 1 | Strong Buy | $6.00 | N/A | Initiates Coverage On | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.